不同干预措施预防臂丛神经阻滞后反跳痛的网状Meta分析
该贝叶斯网状Meta分析纳入22项RCT共1699例上肢手术臂丛阻滞患者,比较六种干预对反跳痛的防治效果。结果显示连续神经阻滞、地塞米松和右美托咪定可降低反跳痛发生率,连续神经阻滞在降低12h和24h疼痛评分方面排名最优,但证据确定性有限,结论仅供探索。
要点
- 连续神经阻滞可降低反跳痛发生率并改善术后12h和24h疼痛评分。
- 地塞米松和右美托咪定也可降低反跳痛发生率,地塞米松还降低12h疼痛评分。
- 证据确定性有限,对反跳痛高危患者可考虑连续神经阻滞,但需进一步验证。
核心结论
- 连续神经阻滞与反跳痛发生率降低及术后12h和24h疼痛评分降低相关。
- 地塞米松和右美托咪定可降低反跳痛发生率,地塞米松还降低12h疼痛评分。
- 证据确定性有限,结论应视为探索性和假设生成性而非确定性结论。
研究设计与样本
- 贝叶斯网状Meta分析,检索PubMed、Web of Science、Embase和Cochrane Library至2025年10月10日。
- 纳入22项随机对照试验,共1699例上肢手术臂丛神经阻滞患者。
- 比较六种干预:地塞米松、艾司氯胺酮、右美托咪定、脂质体布比卡因、连续神经阻滞和联合神经阻滞。
主要发现
- 与安慰剂相比,地塞米松降低反跳痛发生率(OR=0.22,95%CI 0.11至0.42)。
- 与安慰剂相比,右美托咪定降低反跳痛发生率(OR=0.23,95%CI 0.08至0.68)。
- 与安慰剂相比,连续神经阻滞降低反跳痛发生率(OR=0.04,95%CI 0.01至0.33)。
- 与安慰剂相比,地塞米松降低12h术后疼痛评分(MD=-2.54,95%CI -4.76至-0.26)。
- 与安慰剂相比,连续神经阻滞降低12h术后疼痛评分(MD=-3.10,95%CI -5.86至-0.23),联合神经阻滞降低24h疼痛评分(MD=-0.86,95%CI -1.59至-0.13)。
关键数值与推荐
- SUCRA排名显示连续神经阻滞在降低反跳痛及12h/24h疼痛评分方面为最优干预,但反映相对概率而非绝对疗效。
临床怎么用
- 对反跳痛高危患者可考虑连续神经阻滞以平衡疗效与安全性。
- 地塞米松和右美托咪定可作为降低反跳痛发生率的备选干预。
局限性
- 证据确定性有限,结果需进一步验证。
- SUCRA排名反映相对概率而非绝对疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rebound pain is a common transient severe pain after peripheral nerve block subsidence, impairing block efficacy and patient satisfaction. OBJECTIVE: This study aimed to evaluate the preventive and therapeutic effects of six interventions - dexamethasone, esketamine, dexmedetomidine, liposomal bupivacaine, continuous nerve block and combined nerve block (brachial plexus block via multiple approaches) - on rebound pain after upper extremity surgery brachial plexus block to provide evidence-based references for optimising clinical analgesic regimens. DESIGN: Bayesian network meta-analysis. DATASOURCES: PubMed, Web of Science, Embase and Cochrane Library were searched up to 10 October 2025. ELIGIBILITY CRITERIA: Randomised controlled trials (RCTs) assessing the efficacy of the above interventions for rebound pain prevention and treatment after brachial plexus block in upper extremity surgery. RESULTS: A total of 22 RCTs involving 1699 patients were included. Network meta-analysis showed that compared with placebo, dexamethasone [odds ratio (OR) = 0.22 (95% CI, 0.11 to 0.42), dexmedetomidine (OR = 0.23 (95% CI, 0.08 to 0.68)] and continuous nerve block [OR = 0.04 (95% CI, 0.01 to 0.33)] significantly reduced rebound pain incidence. Dexamethasone [mean difference (MD) = -2.54 (95% CI, -4.76 to -0.26)] and continuous nerve block [MD = -3.10 (95% CI, -5.86 to -0.23)] lowered 12-h postoperative pain scores. Compared with placebo, combined nerve block [MD = -0.86 (95% CI, -1.59 to -0.13)] reduced postoperative 24-h pain scores. SUCRA results ranked continuous nerve block as the most favourable intervention for reducing rebound pain and 12-h/24-h postoperative pain scores. These reflect relative probabilities rather than absolute efficacy and require further validation. CONCLUSION: In patients undergoing upper-extremity surgery with brachial plexus block, current network meta-analysis findings suggest that continuous nerve block is associated with a lower incidence of rebound pain and reduced pain scores at 12 and 24 h postoperatively, although further validation is still required. We recommend that continuous nerve block may be considered for patients at high risk of rebound pain to balance efficacy and safety. Given the limited certainty of evidence, these findings should be regarded as exploratory and hypothesis-generating rather than definitive conclusions. TRIAL REGISTRATION: PROSPERO (CRD420251251811).
引用
- Ma W, Chen L, Zhou D, et al. Comparison of the efficacy of different interventions for rebound pain after brachial plexus block in upper extremity surgery: A systematic review and network meta-analysis. Eur J Anaesthesiol. 2026. PMID: 42750605. doi:10.1097/EJA.0000000000002486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。